Literature DB >> 7995017

Therapy with l-deprenyl (selegiline) and relation to abuse liability.

L S Schneider1, P N Tariot, B Goldstein.   

Abstract

This article briefly reviews the clinical aspects and rationale for therapy with l-deprenyl for several neuropsychiatric conditions, including major depression, Alzheimer's disease, and Parkinson's disease. The rationale for the use of l-deprenyl in these conditions is discussed, and evidence for efficacy is reviewed. Lastly, there is a review of the lack of evidence for l-deprenyl's abuse potential and its use as putative nonspecific cognitive enhancer, a so-called "smart drug." Although l-deprenyl itself appears to have no abuse potential, it is theoretically possible that it might potentiate the actions and frequency of dosage and use of various drugs of abuse or dependence. This is as yet an underresearched area, and more work is required.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995017     DOI: 10.1038/clpt.1994.205

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

Authors:  Sevil Yasar; József Gaál; Leigh V Panlilio; Zuzana Justinova; Szecsö V Molnár; Godfrey H Redhi; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 2.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 3.  Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.

Authors:  Fabrizio Schifano; Valeria Catalani; Safia Sharif; Flavia Napoletano; John Martin Corkery; Davide Arillotta; Suzanne Fergus; Alessandro Vento; Amira Guirguis
Journal:  Drugs       Date:  2022-04-02       Impact factor: 9.546

Review 4.  Mechanism-based medication development for the treatment of nicotine dependence.

Authors:  Zheng-xiong Xi; Krista Spiller; Eliot L Gardner
Journal:  Acta Pharmacol Sin       Date:  2009-05-11       Impact factor: 6.150

5.  Selegiline reduces daytime sleepiness in patients with Parkinson's disease.

Authors:  Marco Gallazzi; Marco Mauri; Maria Laura Bianchi; Giulio Riboldazzi; Lucia Princiotta Cariddi; Federico Carimati; Valentina Rebecchi; Maurizio Versino
Journal:  Brain Behav       Date:  2021-03-23       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.